Sixteen health care focussed startups have settled inside the new Harlem Biospace, on W. 127th St.
The Bloomberg administration contributed $626,000 and partnered with Columbia University biomedical engineering professor Sam Sia for the balance of the funding.
Companies include an allergy-testing company, which uses a simple cheek swab to analyze a sneeze; a pharmaceutical drug maker that’s trying to compel cancer cells to “commit suicide,” and inventors developing an MRI-styled device for small animals, Invivo Analytics, which uses imaging to study how diseases ravage mice during pharmaceutical testing.
The facility includes access to a laboratory outfitted with advanced equipment to grow cells, test tissue and analyze toxins; free legal advice from biotech law firm Wilmer Hale; access to topnotch tools and mentors.
About Harlem Biospace
- Harlem Biospace (Hb) is a new biotech incubator, the first of its kind in New York City, to offer affordable shared wet-lab space for competitively-selected entrants
- Situated at the heart of three academic campuses (Columbia University, City College of New York, and future Columbia Manhattanville campus), with easy access to to other major universities and the vibrancy of New York City via the A, B, C, D and 1 trains, eight bus lines, and only three blocks from the Hudson River bike trail and West Side Highway
- Located in the old Factory District of Harlem, an exciting new development attracting technology companies and start-ups, Hb will be housed in the Sweets Building, a former laboratory for confectionery research located at 423 West 127th Street
- Walking distance to the world-famous Red Rooster, the legendary Apollo Theater, Michelin-recommended Jin Ramen, Maison Harlem, multiple Starbucks, and many high-quality independent restaurants and coffee shops